The post hoc analysis of the palliative arm of the SORAMIC trial demonstrated that high baseline IL-6 and IL-8 were associated with significantly shorter overall survival in HCC patients undergoing radioembolization or treated with sorafenib monotherapy. The gene discussed is CXCL8; the disease is hepatocellular carcinoma.